Amgen Inc vs. 4D Molecular Therapeutics, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| AMGN | FDMT | |
|---|---|---|
| Market Cap | $237.52 billion | $874.52 million |
| Revenue (TTM) | $38.09 billion | $92.01 million |
| Net Income (TTM) | $8.74 billion | $-179,175,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | FDMT | |
|---|---|---|
| P/E Ratio | 27.32 | — |
| Price / Book | 20.32 | 2.15 |
| Price / Sales | 6.23 | 9.50 |
AMGN and FDMT split the valuation factors evenly.
Profitability
| AMGN | FDMT | |
|---|---|---|
| Net Margin | 22.95% | -194.74% |
| Return on Equity | 74.80% | -43.95% |
AMGN leads on 2 of 2 profitability factors.
Dividend
| AMGN | FDMT | |
|---|---|---|
| Dividend Yield | 2.29% | — |
| Payout Ratio | 62.61 | — |
AMGN and FDMT split the dividend factors evenly.
Risk & Sentiment
| AMGN | FDMT | |
|---|---|---|
| Short Interest | 1.66% | 0.41% |
FDMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, FDMT overview, FDMT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.